Isospec Analytics lands CHF 400,000 Tech Growth loan from Fondation FIT
What's the deal? The Foundation for Innovation and TechnologyDealroom has a profile for this one. Try Dealroom → has awarded a CHF 400,000 (≈$493,728) Tech Growth loan to Isospec AnalyticsDealroom has a profile for this one. Try Dealroom →, an EPFL spin-off that identifies biological molecules for medical research.
The startup reads molecules like a fingerprint from patient samples — a hundred times faster than existing methods. That helps researchers understand diseases and develop more targeted drugs.
Fellow recipient MYSTONES, an athlete-tracking platform, picked up a smaller CHF 20,000 Digital Grant.
Why now? The loan builds on Isospec's first Tech Seed loan from the foundation in 2024. With the fresh debt, the 10-person team plans to double its analysis capacity and double revenue by the end of 2026.
Isospec has already run pilot projects, notably with Swiss university hospital CHUV.
MYSTONES, meanwhile, is trialling its platform with around 60 athletes. The grant will fund new indicators, a better dashboard, and preparation for first partnerships.
What could go wrong? Doubling capacity and revenue in a single year is steep. Isospec is moving from pilots to scale, where technical and commercial execution gets harder.
MYSTONES faces a fragmented market: athletics remains one of the least digitised sports, and convincing athletes, coaches, and physiotherapists to consolidate onto one tool is no small task.
The signal: Isospec's progression from a 2024 Tech Seed loan to this larger Tech Growth tranche shows the Foundation for Innovation and Technology backing its early-stage bets as they mature, using non-dilutive debt to bridge deep-tech startups from pilot to scale without diluting founders.
Read more: BioAlps
Image credit: "Mass Spectrometry Laboratory (06410488)" by IAEA Imagebank is licensed under CC BY-SA 2.0. To view a copy of this license, visit https://creativecommons.org/licenses/by-sa/2.0/.
